Merger and acquisition activity in Q4 2023 flipped the script after a sluggish third quarter, with 10 transactions valued at $1bn or more and two valued above $10bn, according to data recorded by Evaluate. A total of 39 biopharma M&A deals during the quarter with an aggregate value of nearly $59bn accounted for a more than 60% increase in deal volume, while aggregate value rose more than four-fold from quarter to quarter.
The increase in deal volume from 24 to 39 put the industry’s M&A pace back on track as the sector...